BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 34496932)

  • 1. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
    Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALKBH5 activates FAK signaling through m6A demethylation in
    Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
    Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
    [No Abstract]   [Full Text] [Related]  

  • 3. m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
    Yin X; Zhao S; Zhang M; Xing J; Zhou J; Gao W; Chen L; Zhang Y; Lin L; Lu M; Li W; Shang J; Zhu X
    Gynecol Oncol; 2024 Jan; 180():99-110. PubMed ID: 38086167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B.
    Gong H; Liu L; Cui L; Ma H; Shen L
    Mol Carcinog; 2021 Sep; 60(9):644-657. PubMed ID: 34169564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway.
    Jiang Y; Wan Y; Gong M; Zhou S; Qiu J; Cheng W
    J Cell Mol Med; 2020 Jun; 24(11):6137-6148. PubMed ID: 32329191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
    Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
    Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis.
    Yu H; Yang X; Tang J; Si S; Zhou Z; Lu J; Han J; Yuan B; Wu Q; Lu Q; Yang H
    Mol Ther Nucleic Acids; 2021 Mar; 23():27-41. PubMed ID: 33376625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
    Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
    BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
    Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
    Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis.
    Yang S; Zhao H; Xiao W; Shao L; Zhao C; Sun P
    J Gene Med; 2022 Oct; 24(10):e3446. PubMed ID: 36027869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
    Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
    Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
    Zhang L; Su X
    Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
    Wang D; You D; Li L
    J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
    Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
    Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
    Yang Z; Cai Z; Yang C; Luo Z; Bao X
    EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
    Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
    Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
    Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
    Luo Y; Gui R
    J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.